Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Comparison of associated features and drug treatment between co-occurring unipolar and bipolar disorders in depressed eating disorder patients

  • Mei-Chih Meg Tseng1, 2, 3, 4Email author,
  • Chin-Hao Chang5,
  • Shih-Cheng Liao2, 3 and
  • Hsi-Chung Chen2, 3
BMC PsychiatryBMC series – open, inclusive and trusted201717:81

DOI: 10.1186/s12888-017-1243-0

Received: 12 October 2016

Accepted: 18 February 2017

Published: 27 February 2017

Abstract

Background

To examine the differences of associated characteristics and prescription drug use between co-occurring unipolar and bipolar disorders in patients with eating disorders (EDs).

Methods

Patients with EDs and major depressive episode (MDE) were recruited from psychiatric outpatient clinics. They were interviewed and completed self-administered measures assessing eating and general psychopathology. The prescribed drugs at the index outpatient visit were recorded. Clinical characteristics and prescription drugs of groups with major depressive disorder (ED-MDD), MDE with lifetime mania (ED-BP I), and MDE with lifetime hypomania (ED-BP II) were compared. Continuous variables between groups were compared using generalized linear regression with adjustments of age, gender, and ED subtype for pair-wise comparisons. Multivariate logistic regression with adjustments of age, gender, and ED subtype was employed to estimate adjusted odds ratios with 95% confidence intervals between groups.

Results

Two hundred and twenty-seven patients with EDs had a current MDE. Among them, 17.2% and 24.2% experienced associated manic and hypomanic episodes, respectively. Bipolar I and II patients displayed significantly poorer weight regulation, more severe impulsivity and emotional lability, and higher rates of co-occurring alcohol use disorders than ED-MDD patients. ED-BP I patients were found to have the lowest IQ, poorest working memory, and the most severe depression, suicidality and functional impairment among all patients. Patients with ED-BP II shared affect and behavioral dysregulations with ED-BP I, but had less severe degrees of cognitive and functional impairments than ED-BP I. Patients with ED-BP I were significantly less likely than those in the ED-MDD and ED-BP II groups to be on antidepressant monotherapy, but a great rate (27%) of ED-BP I individuals taking antidepressant monotherapy had potential risk of mood switch during the course of treatment.

Conclusions

Our study identified discriminative features of bipolar I and II disorders from MDD among a group of depressed ED patients. We suggest that the associated mania, hypomania, and mood lability are predictors of clinical severity and should be identified from ED patients presented with depressive features. Accurate diagnosis of bipolar disorders may have implications for pharmacotherapy in patients with EDs.

Keywords

Bipolar I disorder Bipolar II disorder Comorbidity Eating disorders Hypomania Major depression Mania Pharmacotherapy

Background

The relationship between affective disorders and eating disorders (EDs) has been well documented [1], but much of the research focuses exclusively on major depressive disorder (MDD) and EDs. Eating disorders, having high co-morbid rates of psychiatric and physical disorders, have been conceptualized as having features overlapping with bipolar spectrum disorders [2, 3], more specifically between binge-eating related disorder and bipolar II disorder [46]. Studies reveal that lifetime prevalence of bipolar disorders in the ED population ranges from 0% to 34.8% in community or outpatient samples [7, 8], and 36% to 64% among inpatients [9, 10]. A few papers using diagnostic questionnaire or symptom scale have found a rate of 19% bipolar II in individuals with EDs and higher hypomania scores in individuals with binge-eating disorder (BED) than subthreshold BED [11, 12]. Several studies have investigated the correlates of EDs in patients with bipolar disorders [1316], far fewer have examined the effects of bipolar disorder on patients with EDs [6, 8]. No studies have examined the discriminative effects of bipolar I and bipolar II disorders from MDD in patients with EDs. Recent studies adopting the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition(DSM-5)’s [17] broadened criteria of EDs have further substantiated their relationship [6, 18].

Individuals were classified as having lifetime bipolar I disorder if they had ever had a manic episode, defined as a period of seven days or longer with elevated mood, and three other mania symptoms, or with irritable mood plus four other mania symptoms, with the mood disturbance resulting in marked impairment, or hospitalization. Individuals were classified as having lifetime bipolar II disorder if they had had both major depressive episodes (MDEs) and a hypomanic episode, defined by a period of four days or longer with symptom criteria similar to mania, and with an unequivocal change in function, but without a manic episode [19]. In a few other studies, concerns regarding diagnosing individuals with major depression who have a history or concomitant hypomania/mania were addressed (bipolar depression) [2022]. Bipolar disorders are highly prevalent in clinical samples of depressed patients, with bipolar I disorder being diagnosed in 18 − 47.1% of cases, and bipolar II disorder in 7.7 − 45% [23, 24]. Compared with individuals with only major depression (unipolar depression), those with major depression and subthreshold mania/hypomania were found to have significantly higher rates of panic disorder, alcohol use disorders, and behavioral problems [25, 26]. Individuals with bipolar II disorder had even higher rates of anxiety disorders and behavioral problems than those with major depression and subthreshold mania/hypomania [26].

Bipolar II disorder is defined as a milder form of bipolar disorder with regard to hypomanic symptom intensity [17]. However, compared to individuals with bipolar I disorder, individuals with bipolar II disorder may have greater chronicity of illness and spend more time in the depressive phase of their illness [27, 28]. Some researchers have found patterns of comorbidity [15, 29], suicide attempts [14, 30], and functional impairments [31] in bipolar II disorder that are equivalent to those in bipolar I disorder, but others report higher rates of psychiatric comorbidity [30, 32] and suicide attempts [32] in bipolar II compared to bipolar I disorder. Variability in psychiatric comorbidity and functional impairments in bipolar disorders could be related to clinical heterogeneity in sample composition and index illness phase [15, 28].

The evidence of efficacy of drug treatments for EDs has been mostly weak or moderate [33]. Fluoxetine (a selective serotonin reuptake inhibitor) remains to be the only drug approved for bulimia nervosa (BN) until Lisdexamphetamine dimesylate was approved for BED by the US Food and Drug Administration in 2015 [34]. Close monitoring for emergence of hypomanic/manic symptoms is suggested when antidepressant monotherapy is utilized in the treatment of individuals with bipolar depression [35]. Differentiating bipolar I and bipolar II disorders from MDD in ED patients with clinical presentations of major depression is therefore critical for pharmacological treatment.

Based on the above reviews, we hypothesized that depressed ED patients with comorbid bipolar I and bipolar II disorders had differential features from patients with comorbid MDD and those with comorbid bipolar I and II disorders were under-treated with drugs other than antidepressants. This study aimed to examine the associated features between co-occurring bipolar and unipolar disorders in depressed ED patients. We stratify bipolar disorders into bipolar I and bipolar II considering they may have different associated features from unipolar depression. Moreover, we examined the differences of prescription drugs between the three groups of depressed ED patients in clinical practice.

Methods

Participants and procedures

Participants were selected from a group of ED patients (n = 288) who were enrolled upon their first visit to the general psychiatric clinics at a teaching hospital via a two-phase method between August 2010 and July 2014 [6]. The written informed consent was obtained from the patients before enrollment. Individuals with active psychotic symptoms, mental sub-normality, organic mental conditions, and severe medical illnesses were excluded. All study participants were ED patients with current MDE, and were diagnosed by the ED module of the Structured Clinical Interview for DSM-IV-TR Axis I disorders Patient version (SCID-I/P) [36] and Mini International Neuropsychiatric Interview (MINI) . They also underwent face-to-face interviews, assessing comorbid psychiatric diagnoses, history of self-injury behaviors or suicide attempts, and functional impairment. Diagnostic raters were one psychiatrist and two highly trained research assistants with degrees in psychology, who were monitored throughout the study to minimize rater drift. Participants underwent intelligence testing, and completed several questionnaires concerning eating pathology, affect lability, and impulsivity. The drugs prescribed at this index visit were recorded. The Institutional Review Board of National Taiwan University Hospital approved this study.

Measures

SCID-I/P

An ED diagnosis in the last three months and further in the past was established using the SCID-I/P, and adapted to meet the criteria of the DSM-5. Female patients were not required to meet the criteria of amenorrhea for anorexia nervosa (AN). The minimum frequency and duration of binge-eating/purging was once per week for three months for BN and BED [17]. Participants who reported extreme weight or shape concerns, less frequent yet regular binge-eating symptoms, or binge-eating without feelings of distress, and those who did not meet other criteria for the previous disorders, were diagnosed with ED, not otherwise specified (EDNOS).

MINI

The MINI is a short, diagnostic interview for the DSM-IV and ICD-10 psychiatric disorders [37]. It is divided into modules, including diagnoses of major depression, bipolar disorders, anxiety disorders, and alcohol/substance use disorders. The first 40 participant interviews were audiotaped. The κ coefficients of inter-rater reliability for all diagnoses fell between .60 (social phobia) and 1.00 (major depressive episode), except that for substance use disorder (.47). We used the MINI to assess comorbid Axis I psychiatric disorders.

Assessment of functional impairment and suicide risks

The 87-item Structured Interview for Anorexic and Bulimic Disorders, Expert-Assessment (SIAB-EX) covers a wide range of symptoms frequently seen in EDs — body image disturbances, bulimic symptoms, social integration problems, problems associated with sexuality, depression, compulsion, and anxiety [38]. Each item was rated for present status (the last three months) and for maximum pathology in previous years (lifetime). Responses were rated on a severity scale, ranging from 0 for “symptom not present” to 4 for “symptom very much/very severely present”. Following an independent, professional translation of the Chinese version of the SIAB-EX, all items were reviewed by two psychiatrists. The assessment of functional impairment was adopted from item 53, “was your work performance objectively impaired at work or in your household?” Suicide risks were rated by item 69, “did you ever attempt to commit suicide?”, and item 70, “did you ever hurt yourself intentionally?” Severity of suicidal acts and auto-aggressive behaviors was rated according to the number of attempts or seriousness of physical injury. Inter-rater reliability (κ coefficient) for present and lifetime severity of item 53 was .76 and .74, respectively, and ranged from .53 − .78 for items 69 and 70 [39].

Intelligence quotient and working memory assessments

In this study, we used the short form of Wechsler Adult Intelligence Scale—Third Edition (WAIS–III) to assess the intelligence quotient in the groups. It comprises four subtests (Similarities, Matrix Reasoning, Arithmetic, and Digit Symbol substitution) and has been demonstrated to exceed other subtest combinations with respect to validity, content representation, and time saving [40]. This short form AIS-III has been used in several studies on patients with neuropsychiatric disorders [4143]. Scores of working memory were summed by Arithmetic and Digit Span, and were converted to the estimated percentile rank according to the Taiwanese norm [44].

Bulimic Investigatory Test Edinburgh (BITE)

This self-reported measure includes the Symptom Scale (30 items) and the Severity Scale (6 items). The Chinese BITE has good internal consistency (Cronbach’s α = .78 and .52, respectively) and test-retest reliability (intra-class correlation reliability of .86 and .88, respectively) for the two scales [45].

Body Shape Questionnaire (BSQ)

The BSQ was initially developed as a 34-item questionnaire for assessing feelings about body shape, and the behavioral and emotional consequences of such feelings. The BSQ-8 used in this study, which has 8 items derived from the Chinese BSQ-34 [46] has good internal consistency (Cronbach’s alpha, α = .88).

Affect Lability Scale (ALS)

This study adopted an 18-item short form (ALS-18) that was established by selecting items from the original 54-item ALS using exploratory factor analysis with eigenvalues greater than 1 [47]. The original ALS assesses people’s endorsements regarding the tendency of their mood to shift between what they consider normal, to the affective domains of anger, depression, elation, and anxiety, as well as their tendency to oscillate between depression and elation, and between depression and anxiety [48]. The reliability test showed excellent internal consistency for the Chinese version of the ALS-18 (Cronbach’s α = .93) and item-total correlations ranged from .37 to .76.

Beck Depression Inventory (BDI)

The BDI is a 21-item measure examining depressive symptom severity over the last week. Each question has at least four response options of differing intensities. A value ranging 0–3 is assigned to each answer and the total score determines depression severity. The Chinese version of the BDI has shown good reliability and construct validity [49]. and showed good internal consistency in this study (Cronbach’s α = .91).

Barratt Impulsiveness Scale (BIS)

This is a 30-item self-report questionnaire measuring trait impulsivity [50]. The Chinese version of BIS-11 (BIS-11-CH) is modified from the original BIS by removing five items (item 15, 21, 23, 27, and 29) with poor item-total correlations (less than .1) [51]. The remaining 25 items of the BIS-11-CH had a Cronbach’s α of .83, and an intact factorial structure of inability to plan (factor 1), lack of perseverance and self-control (factor 2), and propensity toward novelty-seeking and acting without thinking (factor 3) [51].

Statistical analysis

Clinical and demographic characteristics of groups with MDD (ED-MDD), MDE with lifetime hypomanic episodes (ED-BP II), and MDE with lifetime manic episodes (ED-BP I) were compared. Descriptive statistics were computed to determine means and standard deviations of all continuous variables and frequency distributions for categorical variables. The differences of demographic data between groups were compared using ANOVA and Chi-square tests for continuous variables and categorical variables, respectively. With apparent differences in the distribution of gender and ED subtypes in different comorbid groups, multivariate analyses were therefore applied. Continuous variables between groups were compared using generalized linear regression with adjustments of age, gender, and ED subtype for pair-wise comparisons. Multivariate logistic regression with adjustments of age, gender, and ED subtype was employed to estimate adjusted odds ratios (AORs) with 95% confidence intervals (CIs) between groups. Since there were four subtypes in ED patients, three dummy variables were involved in the regression model. All tests were two-tailed, and p < .05 was considered significant. All statistical analyses were performed using SAS, version 9.4 (Cary, North Carolina, USA).

Results

Demographics and clinical characteristics

Among the ED patients, 227 were diagnosed to have a current MDE. Patients who had current MDE had a later age of onset of ED compared to those who did not have (20.1 ± 6.3 vs. 18.1 ± 4.3). There were no differences of age, gender, and educational levels between the two groups. Table 1 shows the comparison of demographics and distribution of ED subtypes between ED-MDD (58.6%), ED-BP II (24.2%), and ED-BP I (17.2%). No statistically significant differences in age, age at ED onset, and age at depression onset, were observed between groups. Patients with ED-BP I had the lowest educational level among all. The diagnostic distribution of AN, BN, BED, and EDNOS was 41 (18.1%), 101 (44.5%), 58 (25.6%), and 27 (11.9%), respectively. ED-BP I and ED-BP II comprised of higher percentages of BN and BED patients. There were statistically significant differences of sex distribution, age, age of onset of disordered eating, and BMI among ED subtypes (Additional file 1: Table S1.1). There was less female predominance in BED group compared to AN and BN groups. Age differences only existed between BED and BN patients that patients with BED were significantly older and had a later age of onset of eating problems than patients with BN. Patients with BED were the heaviest among all for both current and previous body weight. No statistically significant difference in educational level was observed among ED subgroups. However, other EDs had significantly higher risks of association with generalized anxiety disorder, social phobia, panic disorders, agoraphobia and alcohol use disorder than AN but showed comparable risks of association with most psychiatric disorders between themselves (Additional file 1: Table S1.2).
Table 1

Comparison of demographics and clinical variables for eating disorder patients during major depressive episodes

Variables

Eating disorders with MDD (n = 133)

Eating disorders with bipolar II disorder (n = 55)

Eating disorders with bipolar I disorder (n = 39)

P-value

Gender, female (N, %)

124 (93.2)

46 (83.6)

31 (79.5)

0.0254

Age (years)

27.3 ± 7.4

28.2 ± 7.2

28.4 ± 8.8

0.6184

Age at onset of disordered eating (years)

20.3 ± 6.3

19.2 ± 4.4

20.4 ± 8.1

0.5211

Age at onset of depression (years)

22.8 ± 6.9

22.2 ± 6.7

21.4 ± 8.0

0.6032

Education (years)

14.4 ± 2.3

15.0 ± 2.4

13.0 ± 2.7

0.0005

Eating disorder subtypes (N, %)

   

0.0465

 Anorexia Nervosa

32 (24.1)

4 (7.3)

5 (12.8)

 

 Bulimia Nervosa

60 (45.1)

25 (45.5)

16 (41.0)

 

 Binge eating Disorders

25 (18.8)

19 (34.6)

14 (35.9)

 

 Eating disorders NOS

16 (12.0)

7 (12.7)

4 (10.3)

 

Values in bold type indicated statistically significant

MDD major depressive disorder

Values indicate N (%) or Mean ± SD

Severity of psychopathology and psychiatric comorbidity

Information concerning clinical correlates of the ED with different affective disorders adjusting with sex, age, and ED subtypes is presented in Tables 2 and 3. Patients with ED-BP I had the lowest intelligence quotient and working memory score among all. Compared to the ED-MDD group, those with ED-BP I/BP II had statistically significantly severe degrees of mood lability and impulsiveness, higher current body weight and binge-eating/purging severity. Moreover, patients with ED-BP I/BP II also had a significantly higher rate of comorbidity with alcohol use disorders than ED-MDD patients. Patients with ED-BP I also had a two-fold higher co-occurrence rate of panic disorder than patients with ED-MDD. In comparison to ED-MDD and ED-BP II patients, patients with ED-BP I had more severe depression, mood lability and a greater rate of severe role impairments. The proportion of patients with ED-BP II who had attempted suicide (29%) fell between that of the bipolar I and MDD groups (36% and 17%, respectively). Only the difference between the latter two groups was statistically significant. Considering AN had distinct features of psychiatric co-morbidities from other EDs, we re-analyzed the data after excluding patients with AN. Significant differences of affective lability and current body weight between ED-MDD and ED-BP II group no longer existed and there were no significant difference of percentage of suicidal acts between groups (Additional file 2: Table S2.1 − 2.4). We also provide Additional file 3: Table S3.1 − 3.3 to show the comparison of psychiatric co-morbidity in different ED subtype patients with three groups of affective disorders. Of note, small sample size in some co-morbidity categories may cause difficulties or instability in estimation of statistical significance.
Table 2

Comparison of psychological assessments and BMI among depressed eating disorder patients with or without lifetime hypomania/mania episodes

Variables

Eating disorders with MDD

Eating disorders with bipolar II disorder

Eating disorders with bipolar I disorder

2 vs. 1

3 vs. 1

3 vs. 2

(1)

(2)

(3)

(n = 133)

(n = 55)

(n = 39)

Mean ± SD

Mean ± SD

Mean ± SD

P-value

P-value

P-value

Intelligence quotient

101.2 ± 13.7

100.9 ± 12.7

93.0 ± 14.6

0.6897

0.0085

0.0070

Working memory

54.9 ± 26.5

54.6 ± 29.2

36.4 ± 27.7

0.8742

0.0003

0.0026

Bulimic Investigatory Test Edinburgh

29.7 ± 11.6

31.8 ± 9.1

30.4 ± 11.7

0.0695

0.3315

0.4221

 Symptom subscale

20.4 ± 6.4

21.3 ± 5.4

19.4 ± 6.3

0.2238

0.5335

0.0760

 Severity subscale

9.3 ± 6.6

10.5 ± 5.1

10.9 ± 7.3

0.0612

0.0334

0.7174

Body Shape Questionnaire-8

4.6 ± 1.2

4.9 ± 1.1

4.4 ± 1.3

0.0870

0.5152

0.0465

Beck Depression Inventory

26.2 ± 10.6

26.8 ± 8.8

31.7 ± 9.5

0.9275

0.0079

0.0125

Affective Lability Scale

48.3 ± 8.7

51.6 ± 7.9

56.7 ± 8.6

0.0410

<0.0001

0.0039

Barrett Impulsiveness Scale

58.5 ± 6.0

61.6 ± 6.9

62.4 ± 6.9

0.0018

0.0006

0.5505

BMI, current (kg/m2)

20.3 ± 4.8

23.5 ± 5.5

23.6 ± 6.2

0.0488

0.0430

0.8204

BMI, maximal (kg/m2)

23.8 ± 5.1

26.8 ± 6.4

25.7 ± 5.4

0.0243

0.4736

0.3549

BMI, minimal (kg/m2)

17.0 ± 3.2

18.7 ± 2.9

18.5 ± 3.8

0.2187

0.3413

0.8838

Values in bold type indicated statistically significant

MDD major depressive disorder, BMI Body mass index

adjusted for age, gender, and eating disorder subtypes

Table 3

Comparison of lifetime psychiatric diagnoses among depressed eating disorder patients with or without lifetime hypomania/mania episode

Variables

Eating disorders with MDD

Eating disorders with bipolar II disorder

Eating disorders with bipolar I disorder

2 vs. 1

3 vs. 1

3 vs. 2

(1)

(2)

(3)

(n = 133)

(n = 55)

(n = 39)

N (%)

N (%)

N (%)

AOR (95% CI)

AOR (95% CI)

AOR (95% CI)

Comorbid diagnosis

 Generalized anxiety disorder

50 (37.6)

27 (49.1)

20 (51.3)

1.31 (0.68, 2.54)

1.50 (0.71, 3.17)

1.17 (0.49, 2.79)

 Social phobia

46 (34.6)

23 (41.8)

18 (46.2)

1.29 (0.65, 2.55)

1.63 (0.76, 3.50)

1.21 (0.52, 2.82)

 Panic disorder

16 (12.0)

14 (25.5)

12 (30.8)

2.02 (0.89, 4.60)

2.73 (1.12, 6.69)

1.47 (0.56, 3.80)

 Agoraphobia

27 (20.3)

13 (23.6)

15 (38.5)

0.97 (0.44, 2.11)

2.14(0.95, 4.83)

2.25 (0.87, 5.83)

 Obsessive compulsive disorder

38 (28.6)

19 (34.6)

17 (43.6)

1.23 (0.61, 2.47)

1.80 (0.84, 3.85)

1.52 (0.64, 3.60)

 Post-traumatic stress disorder

15 (11.3)

22 (20.0)

5 (12.8)

1.79 (0.74, 4.33)

1.13 (0.37, 3.44)

0.59 (0.18, 1.89)

 Alcohol abuse/dependence

5 (3.8)

12 (21.8)

12 (30.8)

7.68 (2.41, 24.44)

14.55 (4.37, 48.41)

2.05 (0.74, 5.70)

 Drug abuse/dependence

23 (17.3)

10 (18.2)

10 (25.6)

1.15 (0.49, 2.69)

1.67 (0.69, 4.06)

1.48 (0.53, 4.09)

Functional impairmentb

   

0.87 (0.45, 1.68)a

4.46 (1.80, 11.04) a

5.11 (1.91, 13.72) a

 Severe and very severe

67 (50.4)

26 (47.3)

32 (82.1)

   

 Marked

45 (33.8)

18 (32.7)

7 (18.0)

   

 None and mild

21 (15.8)

11 (20.0)

0

   

Suicide actsc

23 (17.3)

16 (29.1)

14 (35.9)

1.72 (0.80, 3.70)

2.52 (1.10, 5.77)

1.39 (0.57, 3.40)

Auto-aggressive behaviorsd

41 (30.8)

15 (27.3)

18 (46.2)

0.81 (0.39, 1.67)

1.92 (0.89, 4.11)

2.18 (0.89, 5.37)

AOR: odd ratio adjusted for age, gender, and eating disorder subtypes

Values in bold type indicated statistically significant

MDD major depressive disorder

Impairments and suicide were assessed using the Structured Interview on Anorexic and Bulimic Disorder, Expert-Assessment (SIAB-EX)

aPatients with severe and very severe impairments compared with all others

b: rated by the Item 53 ‘Was your work performance objectively impaired at work or in your household ?”. Severity of impairment is rated from 0 (=no) to 4 (=very severe)

c: rated by the item 69 ‘Did you ever attempt to commit suicide?’

d: rated by the Item 70 ‘Did you ever hurt yourself intentionally?’. Severity of suicidal acts and auto-aggressive behaviors is rated from 0 (= symptom not present) to 4 (= symptom very much/very severely present) according to the number of attempts or seriousness of physical injury; here suicide acts indicated the severity more than one serious attempt or many minor attempts and auto-aggressive behaviors indicated the severity more than marked degree

Table 4

Comparison of pharmacotherapy among depressed eating disorder patients with or without lifetime hypomania/mania episode at enrollment

Variables

Eating disorders with MDD

Eating disorders with bipolar II disorder

Eating disorders with bipolar I disorder

2 vs. 1

3 vs. 1

3 vs. 2

(1)

(2)

(3)

(n = 133)

(n = 55)

(n = 39)

N (%)

N (%)

N (%)

AOR (95% CI)

AOR (95% CI)

AOR (95% CI)

Antidepressant monotherapy

61 (48.0)

31 (56.4)

10 (27.0)

1.23 (0.62, 2.42)

0.35 (0.15, 0.83)

0.28 (0.11, 0.72)

mood stabilizer monotherapy

0

1 (1.8)

0

NA

NA

NA

Atypical antipsychotic monotherapy

32 (25.2)

6 (10.9)

9 (24.3)

0.41 (0.15, 1.09)

1.04 (0.41, 2.61)

2.65 (0.82, 8.59)

Antidepressant plus mood stabilizers

1 (0.8)

0

1 (2.7)

NA

NA

NA

Antidepressant plus antipsychotic

17 (13.4)

10 (18.2)

9 (24.3)

1.44 (0.56, 3.47)

2.09 (0.81, 5.37)

1.36 (0.46, 4.03)

Antidepressant plus mood stabilizers and antipsychotics

1 (0.8)

1 (1.8)

1 (2.7)

2.26 (0.13, 39.12)

4.00 (0.23, 68.78)

1.78 (0.10, 30.80)

Any antidepressant

80 (63.0)

42 (76.4)

21 (56.8)

1.70 (0.78, 3.72)

0.70 (0.31, 1.60)

0.38 (0.15, 0.99)

Any mood stabilizer

5 (3.9)

3 (5.5)

6 (16.2)

1.01 (0.25, 4.88)

3.95 (1.06, 14.71)

3.96 (0.90, 17.44)

Any atypical antipsychotic

51 (40.2)

17 (30.9)

21 (56.8)

0.72 (0.36, 1.47)

2.13 (0.97, 4.65)

2.92 (1.18, 7.20)

MDD major depressive disorder

Data mission for 6 and 2 persons in eating disorders with MDD and eating disorders with bipolar I disorder, respectively

AOR: odd ratio adjusted for age, gender, and eating disorder subtypes

Values in bold type indicated statistically significant

Pharmacotherapy among different groups

Antidepressants were the most frequently prescribed medication (63.0%), either as monotherapy (44.9%) or concomitantly with other drugs, for ED patients with a current MDE (Table 4). The percentage of patients prescribed antidepressant monotherapy in ED-BP I and ED-BP II was statistically significantly different from ED-MDD groups. Although ED-BP I patients were significantly less likely than those in the ED-MDD (AOR = 0.35, 95% CI = 0.15 − 0.83, p = .017) and ED-BP II (AOR = 0.28, 95% CI = 0.11 − 0.72, p = .008) groups to be on antidepressant monotherapy, a great rate of ED-BP I individuals taking antidepressant monotherapy (27%) was exposed to the risk of mood switch during the course of treatment. The second most commonly prescribed pharmacotherapy was atypical antipsychotic monotherapy (20.7%), followed by combination therapy of antidepressants and atypical antipsychotics (15.9%). Patients with ED-BP I disorder were more likely to be taking atypical antipsychotics than those with ED-BP II disorder, and were also more likely to be taking mood stabilizers and less likely to be taking antidepressants than those with ED-MDD. No differences presented in other comparisons between groups.

Discussion

Using structured interviews and self-administered questionnaires, we found that lifetime hypomania and mania were prevalent in ED patients with a current MDE, with bipolar I disorder being diagnosed in 17.2% and bipolar II in 24.2% of patients. There were varying associated psychopathology across groups with different comorbidities. ED-BP I and ED-BP II patients tended to have a greater body weight and increased suicidality, greater affect lability, impulsiveness, and a higher rate of alcohol use disorder than ED-MDD patients. Patients with ED-BP I reported the most severe binge-eating, depression, affect lability, impaired intelligence and working memory, and lifetime functional impairments. Although patients with ED-BP I had statistically significantly severe degrees of impulsiveness and higher co-occurrence rates of panic disorder and alcohol use disorder than patients with ED-MDD, they did not differ from patients with ED-BP II in these dimensions. Twenty-seven percent of ED-BP I patients were treated with antidepressant monotherapy that left this subgroup of patients unprotected from future mood switch and increased likelihood of chronicity of illness.

This study successfully illustrated heterogeneity among ED patients with a current MDE. Anxiety, impulsivity, suicide attempts, and alcohol/drug use disorders are prevailing comorbidities observed in ED patients [5, 5254]. Our study found that ED-BP I patients had a two-fold higher rate of comorbidity with panic disorder and ED-BP I and ED-BP II patients had a higher rate of comorbidity with alcohol use disorders (14- and 7-fold, respectively) compared to those with ED-MDD. This observation was consistent with prior findings that individuals with bipolar spectrum disorders had significantly higher rates of many psychiatric disorders, including panic disorder and alcohol use disorders [31]. It is noteworthy that prior suicide attempts were reported by approximately 30% of our ED patients with bipolar I and bipolar II disorders and that the suicide risk was two-fold higher in this population compared to ED patients with comorbid MDD. These findings were in line with two earlier studies reporting that suicidal or self-destructive behavior in ED patients is associated with bipolar disorder [55, 56]. The presence of EDs has been implicated as a marker of clinical severity in patients with bipolar disorders, including more frequent suicide attempts than among those without EDs [13, 14, 57]. The co-existence of EDs and bipolar disorders, especially bipolar I, indicates greater risks of suicide and psychiatric comorbidity in both groups of patients.

It is interesting to notice that heterogeneity also existed between patients with ED-BP I and ED-BP II when compared to those with ED-MDD. Patients with ED-BP II appeared to share affect and behavioral dysregulations with ED-BP I, but did not have as severe degrees of cognitive and functional impairments as ED-BP I. This finding added more evidence to support earlier concerns that failure to recognize the history or co-existence of hypomania symptoms in patients with MDE might result in no or correspondingly inadequate treatment as discussed as follows.

Although the benefits of antidepressant monotherapy remain unclear in the treatment of bipolar depression [35], it is the most common initial prescription in all ED patients with a current MDE. Patients with ED-bipolar II had a comparable rate of being prescribed antidepressant monotherapy with patients with ED-MDD, and were more likely currently taking antidepressants monotherapy than patients with ED-bipolar I, leaving the concern that patients with hypomania might be less likely than those with mania to be identified from patients with MDEs or they had received adequate treatment for associated problems by taking antidepressants monotherapy. Antidepressant monotherapy may, however, expose ED patients with comorbid bipolar spectrum disorders to a potentially increased risk of mood lability and poor impulse control, among other dangerous consequences. There is a growing consensus from experts that antidepressant monotherapy should be avoided in patients with bipolar I disorder, patients with bipolar depression with two or more concomitant manic symptoms, and in bipolar patients with high mood instability or with a history of rapid cycling [35, 58]. Several researchers have addressed the role of affect lability or hypomania symptoms in binge-eating behaviors or other impulsive behaviors in ED patients [12, 59]. With comparison to the recognition of history of mania, hypomania, or mixed episodes, mood lability may be a more obvious indicator to avoid antidepressant monotherapy.

Several open series studies [60] or double-blind placebo-controlled studies [6163] have demonstrated that atypical antipsychotics, e.g. olanzapine and quetiapine, have efficacy in reducing depressive or obsessive symptoms and causing weight gain in patients with AN. However, studies examining the efficacy of atypical antipsychotics in reducing binge-eating in patients with BN are scarce. Use of atypical antipsychotics in the treatment of EDs was not uncommon among our patients (40.2% − 56.8%). Although meta-analysis studies have yielded disappointing result [64], it is believed that some ED patients might benefit from antipsychotic medication [33, 65, 66]. Mood stabilizers have not had a large role in the treatment of EDs and topiramate (an anticonvulsant) had well-established efficacy in reducing binge-eating frequency and weight loss [67]. Both were not used frequently in our sample. Our results provide support for the rationale of the use of antipsychotics or mood stabilizers in the treatment of ED patients if comorbid bipolar disorders can be identified via the recognition of associated features reported in this present study. We hypothesize that treatment effects on affect lability and impulsivity might offset adverse effects of weight gain by taking antipsychotics or mood stabilizers and are beneficial for eating and weight control in a subgroup of ED patients with co-occurring bipolar disorders. However, further work to determine the indication and efficacy of atypical antipsychotics or mood stabilizers in the treatment of EDs is merited.

This study did have a few methodological limitations. The first was the small sample size. Consequently, all types of EDs were grouped together. Different ED subtypes may have different risks of association with psychiatric morbidities that would have influences on our current findings. Second, participants were selected in a tertiary center in a non-Western country, and thus, the sample may not be representative of the population with EDs elsewhere. Third, the medication use reported in this study was per psychiatrists’ prescriptions from their initial encounters with patients. We did not follow up any changes in prescription at subsequent visits, or check patients’ compliance in taking these medications. Finally, this is a cross-sectional design, and diagnosis of lifetime hypomania/mania was per patients’ self-reports. Recall bias may exist. In spite of these limitations, to our knowledge, this is a pioneering work, examining the influence of bipolar disorders on ED patients during MDEs. It has important implications for pharmacotherapy in the management of ED.

Conclusions

Our study identified discriminative features of bipolar I and II disorders from MDD among a group of depressed ED patients. It is critical to recognize the presence of mood lability, a history of hypomanic/manic episodes, and other features associated with bipolar disorders, to evaluate if individuals with major depression may have hidden bipolarity. The co-occurrence of bipolar disorders in ED patients may provide clues indicating disease severity and the likelihood of presentation of impulsiveness, suicidality, psychiatric comorbidities, and even cognitive and functional impairments. The use of antidepressants in patients with EDs should be considered carefully if they have co-existent dysregulated mood and behavioral symptoms.

Declarations

Acknowledgments

The authors acknowledge statistical assistance provided by the Taiwan Clinical Trial Bioinformatics and Statistical Center, Training Center, and Pharmacogenomics Laboratory (Which is founded by National Research Program for Biopharmaceuticals (NRPB) at the Ministry of Science and Technology of Taiwan; MOST 103-2325-B-002-033). And the Department of Medical Research in National Taiwan University Hospital.

Funding

Data collection of this study was supported by grants from the National Science Council of Taiwan (NSC 99-2410-H-002-094, 100-2410-H-002 -039-MY2 and 102-2410-H-002 -047), and manuscript preparation was supported by two more grants from the Ministry of Science and Technology of Taiwan and the Far Eastern Memorial Hospital (MOST 104-2314-B-418-016 and FEMH 104-2314-B-418-016).

Availability of data and materials

The datasets during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

MMT initiated the research ideation, developed research design, collected data, and was a major contributor in writing the manuscript; CHC analyzed and interpreted the data, and wrote the manuscript regarding “statistical analysis”; SCL participated research initiation and design, data collection, and interpretation of study results; HCC helped data collection, and interpretation of study results. All authors read and approved the final manuscript."

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The written informed consent was obtained from all the participants before enrollment. The Institutional Review Board of National Taiwan University Hospital approved this study.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Psychiatry, Far Eastern Memorial Hospital
(2)
Department of Psychiatry, National Taiwan University College of Medicine
(3)
Department of Psychiatry, National Taiwan University Hospital
(4)
Department of Nursing, Oriental Institute of Technology
(5)
Department of Medical Research, National Taiwan University Hospital

References

  1. Godart NT, Perdereau F, Rein Z, Berthoz S, Wallier J, Jeammet P, et al. Comorbidity studies of eating disorders and mood disorders. Critical review of the literature. J Affect Disord. 2007;97:37–49.View ArticlePubMedGoogle Scholar
  2. Perugi G, Akiskal HS. The soft bipolar spectrum redefined: focus on the cyclothymic, anxious-sensitive, impulse-dyscontrol, and binge-eating connection in bipolar II and related conditions. Psychiatr Clin North Am. 2002;25:713–37.View ArticlePubMedGoogle Scholar
  3. McElroy SL, Kotwal R, Keck Jr PE, Akiskal HS. Comorbidity of bipolar and eating disorders: distinct or related disorders with shared dysregulations? J Affect Disord. 2005;86:107–27.View ArticlePubMedGoogle Scholar
  4. Lunde AV, Fasmer OB, Akiskal KK, Akiskal HS, Oedegaard KJ. The relationship of bulimia and anorexia nervosa with bipolar disorder and its temperamental foundations. J Affect Disord. 2009;115:309–14.View ArticlePubMedGoogle Scholar
  5. Hudson JI, Hiripi E, Pope Jr HG, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007;61:348–58.View ArticlePubMedGoogle Scholar
  6. Tseng M-CM, Chang C-H, Chen K-Y, Liao S-C, Chen H-C. Prevalence and correlates of bipolar disorders in patients with eating disorders. J Affect Disord. 2016;190:599–606.View ArticlePubMedGoogle Scholar
  7. McElroy SL, Guerdjikova A, Lavanier S, O'Melia A. Bipolar disorder with co-occurring eating disorders: prevalence and pharmacotherapeutic implications. Focus. 2011;9:435–48.View ArticleGoogle Scholar
  8. Campos R, dos Santos JR, Cordas T, Angst J, Moreno R. Occurrence of bipolar spectrum disorder and comorbidities in women with eating disorders. Int J Bipolar Disord. 2013;1:25.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Hudson J, Pope H, Yurgelun-Todd D. Bulimia and major affective disorder: Experience with 105 patients. Psychiatrie et Psychobiologie. 1988;3:37–47.Google Scholar
  10. Simpson SG, Al-Mufti R, Andersen AE, DePaulo JRJ. Bipolar II affective disorder in eating disorder inpatients. J Nerv Ment Dis. 1992;180:719–22.View ArticlePubMedGoogle Scholar
  11. Nagata T, Yamada H, Teo A, Yoshimura C, Kodama Y, van Vliet I. Using the mood disorder questionnaire and bipolar spectrum diagnostic scale to detect bipolar disorder and borderline personality disorder among eating disorder patients. BMC Psychiatry. 2013;13:69.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Amianto F, Lavagnino L, Leombruni P, Gastaldi F, Daga GA, Fassino S. Hypomania across the binge eating spectrum. A study on hypomanic symptoms in full criteria and sub-threshold binge eating subjects. J Affect Disord. 2011;133:580–3.View ArticlePubMedGoogle Scholar
  13. McElroy SL, Frye MA, Hellemann G, Altshuler L, Leverich GS, Suppes T, et al. Prevalence and correlates of eating disorders in 875 patients with bipolar disorder. J Affect Disord. 2011;128:191–8.View ArticlePubMedGoogle Scholar
  14. Goffin KC, Dell’Osso B, Miller S, Wang PW, Holtzman JN, Hooshmand F, et al. Different characteristics associated with suicide attempts among bipolar I versus bipolar II disorder patients. J Psychiatr Res. 2016;76:94–100.View ArticlePubMedGoogle Scholar
  15. Mantere O, Melartin TK, Suominen K, Rytsala HJ, Valtonen HM, Arvilommi P, et al. Differences in Axis I and II comorbidity between bipolar I and II disorders and major depressive disorder. J Clin Psychiatry. 2006;67:584–93.View ArticlePubMedGoogle Scholar
  16. Wildes J, Marcus M, Fagiolini A. Prevalence and correlates of eating disorder co-morbidity in patients with bipolar disorder. Psychiatry Res. 2008;161:51–8.View ArticlePubMedPubMed CentralGoogle Scholar
  17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). 5th ed. Washington: American Psychiatric Association; 2013.View ArticleGoogle Scholar
  18. McElroy SL, Crow S, Blom TJ, Biernacka JM, Winham SJ, Geske J, et al. Prevalence and correlates of DSM-5 eating disorders in patients with bipolar disorder. J Affect Disord. 2016;191:216–21.View ArticlePubMedGoogle Scholar
  19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR). 4th ed. Washington: American Psychiatric Association; 2000.View ArticleGoogle Scholar
  20. Mitchell PB, Goodwin GM, Johnson GF, Hirschfeld RMA. Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disord. 2008;10:144–52.View ArticlePubMedGoogle Scholar
  21. Hirschfeld RM. Differential diagnosis of bipolar disorder and major depressive disorder. J Affect Disord. 2014;169 Suppl 1:S12–6.View ArticlePubMedGoogle Scholar
  22. Cuellar AK, Johnson SL, Winters R. Distinctions between bipolar and unipolar depression. Clin Psychol Rev. 2005;25:307–39.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Benazzi F. Prevalence of bipolar II disorder in outpatient depression: a 203-case study in private practice. J Affect Disord. 1997;43:163–6.View ArticlePubMedGoogle Scholar
  24. Akiskal HS, Bourgeois ML, Angst J, Post R, Möller H-J, Hirschfeld R. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord. 2000;59 Suppl 1:S5–S30.View ArticlePubMedGoogle Scholar
  25. Zimmermann P, Brückl T, Nocon A, Pfister H, Lieb R, Wittchen H, et al. Heterogeneity of DSM-IV major depressive disorder as a consequence of subthreshold bipolarity. Arch Gen Psychiatry. 2009;66:1341–52.View ArticlePubMedGoogle Scholar
  26. Angst J, Cui L, Swendsen J, Rothen S, Cravchik A, Kessler RC, et al. Major depressive disorder with subthreshold bipolarity in the national comorbidity survey replication. Am J Psychiatry. 2010;167:1194–201.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Judd LL, Akiskal HS, Schettler PJ, Coryell W, Maser J, Rice JA, et al. The comparative clinical phenotype and long term longitudinal episode course of bipolar I and II: a clinical spectrum or distinct disorders? J Affect Disord. 2003;73:19–32.View ArticlePubMedGoogle Scholar
  28. Mantere O, Suominen K, Valtonen HM, Arvilommi P, Leppamaki S, Melartin T, et al. Differences in outcome of DSM-IV bipolar I and II disorders. Bipolar Disord. 2008;10:413–25.View ArticlePubMedGoogle Scholar
  29. Suppes T, Leverich GS, Keck PE, Nolen WA, Denicoff KD, Altshuler LL, et al. The Stanley Foundation Bipolar Treatment Outcome Network. II. Demographics and illness characteristics of the first 261 patients. J Affect Disord. 2001;67:45–59.View ArticlePubMedGoogle Scholar
  30. Dell'Osso B, Holtzman JN, Goffin KC, Portillo N, Hooshmand F, Miller S, et al. American tertiary clinic-referred bipolar II disorder compared to bipolar I disorder: more severe in multiple ways, but less severe in a few other ways. J Affect Disord. 2015;188:257–62.View ArticlePubMedGoogle Scholar
  31. Merikangas K, Jin R, He J, Kessler R, Lee S, Sampson N, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68:241–51.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Baek JH, Park DY, Choi J, Kim JS, Choi JS, Ha K, et al. Differences between bipolar I and bipolar II disorders in clinical features, comorbidity, and family history. J Affect Disord. 2011;131:59–67.View ArticlePubMedGoogle Scholar
  33. McElroy SL, Guerdjikova AI, Mori N, Keck Jr PE. Psychopharmacologic treatment of eating disorders: emerging findings. Curr Psychiatry Rep. 2015;17:35.View ArticlePubMedGoogle Scholar
  34. McElroy SL, Hudson JI, Mitchell JE, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: A randomized clinical trial. JAMA Psychiatry. 2015;72:235–46.View ArticlePubMedGoogle Scholar
  35. Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170:1249–62.View ArticlePubMedPubMed CentralGoogle Scholar
  36. First MB, Spitzer R, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders. Patient edition. New York: Biometrics Research Department, New York State Psychiatric Institute; 2002.Google Scholar
  37. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22–33.PubMedGoogle Scholar
  38. Fichter MM, Quadflieg N. The Structured Interview for Anorexic and Bulimic disorders for DSM-IV and ICD-10 (SIAB-EX): reliability and validity. Eur Psychiatry. 2001;16:38–48.View ArticlePubMedGoogle Scholar
  39. Tseng M-CM, Chen K-Y, Chang C-H, Liao S-C, Chen H-C. Variables influencing presenting symptoms of patients with eating disorders at psychiatric outpatient clinics. Psychiatry Res. 2016;238:338–44.View ArticlePubMedGoogle Scholar
  40. Chen HY, Hua MS, Zhu J, Chen YH. Selection of Factor-Based WAIS-III Tetrads in the Taiwan Standardization Sample: A Guide to Clinical Practice. Chin J Psychol. 2008;50:91–109.Google Scholar
  41. Yu RL, Wu RM, Tai CH, Lin CH, Hua MS. Feeling-of-knowing in episodic memory in patients with Parkinson's disease with various motor symptoms. Mov Disord. 2010;25:1034–9.View ArticlePubMedGoogle Scholar
  42. Kao YC, Liu YP, Lien YJ, Lin SJ, Lu CW, Wang TS, et al. The influence of sex on cognitive insight and neurocognitive functioning in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013;44:193–200.View ArticlePubMedGoogle Scholar
  43. Li YH, Chiu MJ, Yeh ZT, Liou HH, Cheng TW, Hua MS. Theory of mind in patients with temporal lobe epilepsy. J Int Neuropsychol Soc. 2013;19:594–600.View ArticlePubMedGoogle Scholar
  44. Chen Y, Chen H. Wechsler Adult Intelligence Scale-Third Edition (WAIS-III) Manual for Taiwan (Text in Chinese). Taipei: The Chinese Behavioral Science Corporation; 2002.Google Scholar
  45. Tseng M-CM, Fang D, Lee M-B. Comparative validity of the chinese versions of the bulimic inventory test edinburgh and eating attitudes test for DSM-IV eating disorders among high school dance and nondance students in Taiwan. Int J Eat Disord. 2014;47:105–21.View ArticlePubMedGoogle Scholar
  46. Tseng MM-C, Fang D, Lee M-B, Chie W-C, Liu J-P, Chen WJ. Two-phase survey of eating disorders in gifted dance and non-dance high-school students in Taiwan. Psychol Med. 2007;37:1085–96.View ArticlePubMedGoogle Scholar
  47. Oliver MN, Simons JS. The affective lability scales: development of a short-form measure. Pers Individ Dif. 2004;37:1279–88.View ArticleGoogle Scholar
  48. Harvey PD, Greenberg BR, Serper MR. The Affective Lability Scales: development, reliability, and validity. J Clin Psychol. 1989;45:786–93.View ArticlePubMedGoogle Scholar
  49. Shek DTL. Reliability and factorial structure of the chinese version of the Beck Depression Inventory. J Clin Psychol. 1990;46:35–43.View ArticlePubMedGoogle Scholar
  50. Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt impulsiveness scale. J Clin Psychol. 1995;51:768–74.View ArticlePubMedGoogle Scholar
  51. Li CS, Chen SH. Obsessive-compulsiveness and impulsivity in a non-clinical population of adolescent males and females. Psychiatry Res. 2007;149:129–38.View ArticlePubMedGoogle Scholar
  52. Bulik CM, Klump KL, Thornton L, Kaplan AS, Devlin B, Fichter MM, et al. Alcohol use disorder comorbidity in eating disorders: a multicenter study. J Clin Psychiatry. 2004;65:1000–6.View ArticlePubMedGoogle Scholar
  53. Franko DL, Keel PK. Suicidality in eating disorders: occurrence, correlates, and clinical implications. Clin Psychol Rev. 2006;26:769–82.View ArticlePubMedGoogle Scholar
  54. Swinbourne J, Hunt C, Abbott M, Russell J, St Clare T, Touyz S. The comorbidity between eating disorders and anxiety disorders: prevalence in an eating disorder sample and anxiety disorder sample. Aust N Z J Psychiatry. 2012;46:118–31.View ArticlePubMedGoogle Scholar
  55. Stein D, Lilenfeld LRR, Wildman PC, Marcus MD. Attempted suicide and self-injury in patients diagnosed with eating disorders. Compr Psychiatry. 2004;45:447–51.View ArticlePubMedGoogle Scholar
  56. Favaro A, Santonastaso P, Monteleone P, Bellodi L, Mauri M, Rotondo A, et al. Self-injurious behavior and attempted suicide in purging bulimia nervosa: associations with psychiatric comorbidity. J Affect Disord. 2008;105:285–9.View ArticlePubMedGoogle Scholar
  57. Brietzke E, Moreira CLR, Toniolo RA, Lafer B. Clinical correlates of eating disorder comorbidity in women with bipolar disorder type I. J Affect Disord. 2011;130:162–5.View ArticlePubMedGoogle Scholar
  58. Malhi GS, Bassett D, Boyce P, Bryant R, Fitzgerald PB, Fritz K, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49:1087–206.View ArticlePubMedGoogle Scholar
  59. Anestis MD, Peterson CB, Bardone-Cone AM, Klein MH, Mitchell JE, Crosby RD, et al. Affective lability and impulsivity in a clinical sample of women with bulimia nervosa: the role of affect in severely dysregulated behavior. Int J Eat Disord. 2009;42:259–66.View ArticlePubMedGoogle Scholar
  60. Court A, Mulder C, Kerr M, Yuen HP, Boasman M, Goldstone S, et al. Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: a pilot study. J Psychiatr Res. 2010;44:1027–34.View ArticlePubMedGoogle Scholar
  61. Bissada H, Tasca GA, Barber AM, Bradwejn J. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2008;165:1281–8.View ArticlePubMedGoogle Scholar
  62. Powers PS, Klabunde M, Kaye W. Double-blind placebo-controlled trial of quetiapine in anorexia nervosa. Eur Eat Disor Rev. 2012;20:331–4.View ArticleGoogle Scholar
  63. Brambilla F, Garcia CS, Fassino S, Daga GA, Favaro A, Santonastaso P, et al. Olanzapine therapy in anorexia nervosa: psychobiological effects. Int Clin Psychopharmacol. 2007;22:197–204.View ArticlePubMedGoogle Scholar
  64. Lebow J, Sim LA, Erwin PJ, Murad MH. The effect of atypical antipsychotic medications in individuals with anorexia nervosa: a systematic review and meta-analysis. Int J Eat Disord. 2013;46:332–9.View ArticlePubMedGoogle Scholar
  65. Dold M, Aigner M, Klabunde M, Treasure J, Kasper S. Second-generation antipsychotic drugs in anorexia nervosa: a meta-analysis of randomized controlled trials. Psychother Psychosom. 2015;84:110–6.View ArticlePubMedGoogle Scholar
  66. Takaki M, Okabe N. Aripiprazole may be effective as an add-on treatment in bulimic symptoms of eating disorders. J Clin Psychopharmacol. 2015;35:93–5.View ArticlePubMedGoogle Scholar
  67. Woldeyohannes HO, Soczynska JK, Maruschak NA, Syeda K, Wium-Andersen IK, Lee Y, et al. Binge eating in adults with mood disorders: Results from the International Mood Disorders Collaborative Project. Obes Res Clin Pract. 2016;10:531–43.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement